All In MedTech

Device Trial Radar · NCT01204801

Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors

Randomized Pivotal Trial to Assess the Safety and Efficacy of Preoperative Focused Microwave Thermotherapy Plus Preoperative Chemotherapy Versus Preoperative Chemotherapy Alone for Cytoreduction of Large Breast Cancer in Female Patients With Intact Breast

Last checked: Nov 19, 2026Latest source record: Sep 24, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingTitle says "pivotal". Randomized with 238 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

238

Planned (sponsor's estimate)

Start

Nov 2010

Primary completion

Dec 2016

Study completion Dec 2016

Sponsor

Lead sponsor
Medifocus, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Sep 17, 2010

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this randomized Phase III study is to determine whether preoperative focused microwave heat treatment and chemotherapy combined are more effective than preoperative chemotherapy alone in the treatment of large breast cancer tumors in the intact breast. Combining heat with chemotherapy before surgery might shrink the tumor so that it can be removed in a breast conserving surgery (lumpectomy) instead of a mastectomy.

Conditions

  • Breast Cancer

Interventions

  • Focused Microwave ThermotherapyDevice

    Anthracycline Doxorubicin 60mg/m2 (or Epirubicin 100 mg/m2) + Standard of Care chemotherapy and drugs + Thermotherapy. Thermotherapy at first 3 chemotherapy treatments for Anthracycline chemotherapy nominally every 21±7 days plus Standard of Care chemotherapy. (A targeted tumor temperature of 44ºC (plus or minus 1.5ºC) and a targeted thermal dose of 80 equivalent treatment minutes (plus or minus 20 treatment minutes)). In the event that the targeted minimum cumulative thermal dose of 180 equivalent treatment minutes is not achieved in the first three treatments, an optional fourth thermotherapy treatment may be administered in combination with the fourth course of Anthracycline and standard of care chemotherapy. Standard of care (including breast imaging, drugs, and radiation) will be provided to all eligible subjects during and following the above study treatments.

  • Chemotherapy (control)Drug

    Anthracycline Doxorubicin 60mg/m2 (or Epirubicin 100 mg/m2) + Standard of Care chemotherapy and drugs. Anthracycline chemotherapy nominally every 21±7 days. Standard of care (including breast imaging, drugs, and radiation) will be provided to all eligible subjects during and following the above study treatments.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Tumor Shrinkage (ultrasound)Time frame: Prior to Surgery, on average 4 months from the start of treatment

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Dr. William Dooley

    Oklahoma City, Oklahoma · Recruiting

  • Ville-Marie Medical Centre

    Montreal, Quebec, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.